Current Edition


FDA places stricter limits on J&J’s COVID-19 vaccine after review of rare side effect

Dive Brief: The Food and Drug Administration has determined that the risk of a rare, but serious, clotting syndrome tied to Johnson & Johnson’s COVID-19 …

Continue Reading →

J&J cuts COVID vaccine sales forecasts, citing high supplies and lagging demand

Dive Brief: Johnson & Johnson is lowering its forecast for COVID-19 vaccine sales, announcing Tuesday it will has suspended its guidance of $3 billion to …

Continue Reading →

J&J to explore RNA reprogramming with Remix research deal

Dive Brief: Johnson & Johnson is partnering with Remix Therapeutics to develop drugs that are meant to reprogram how RNA is processed, becoming the latest …

Continue Reading →

FDA extends review of J&J, Legend’s cell therapy for multiple myeloma

Abecma and cilta cel are part of an emerging class of multiple myeloma treatments that target a protein called BCMA, which is found on cancer …

Continue Reading →
coronavirus vaccine

J&J foresees end to not-for-profit sales of coronavirus vaccine

J&J has recorded far fewer sales of its coronavirus vaccine than competitors Pfizer and Moderna, partly due to its not-for-profit pricing but also to a …

Continue Reading →
Centers of Disease Control and Prevention

J&J asks FDA to clear booster dose of its coronavirus vaccine

For the past several months, one of the many questions hanging over the booster debate has ben what do with people who got J&J’s shot. …

Continue Reading →

After coronavirus success, J&J hits setback with HIV vaccine

Before J&J become one of three companies that earned Food and Drug Administration approval for a coronavirus vaccine, the pharma was already a leader in …

Continue Reading →
autoimmune diseases

With new results, J&J’s $1B gamble on a targeted inflammation drug faces long odds

Izencitinib is a JAK inhibitor, a type of drug that blocks an enzyme involved in inflammation. The drug class is well-established, having already produced multiple …

Continue Reading →

J&J’s Janssen to Acquire BeneVir for $1 Billion

Janssen Biotech, part of Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson (J&J), announced on May 2, 2018 that it has entered into a …

Continue Reading →